Bone Marrow Transplant
-
Publication Venue For
- Revisiting a single day salvage conditioning following graft failure.. 57:1845-1847. 2022
- Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.. 57:1615-1619. 2022
- Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation.. 57:671-673. 2022
- Outcomes of pediatric patients with therapy-related myeloid neoplasms.. 56:2997-3007. 2021
- The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae.. 56:2889-2896. 2021
- Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation.. 56:2826-2833. 2021
- Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.. 56:2319. 2021
- Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.. 56:2108-2117. 2021
- Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.. 56:1238-1247. 2021
- Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.. 56:137-143. 2021
- To D or not to D: vitamin D in hematopoietic cell transplantation.. 55:2060-2070. 2020
- Acute respiratory failure and the kinetics of neutrophil recovery in pediatric hematopoietic cell transplantation: a multicenter study.. 55:341-348. 2020
- Correction to: Acute respiratory failure and the kinetics of neutrophil recovery in pediatric hematopoietic cell transplantation: a multicenter study.. 55:476. 2020
- Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients.. 54:1443-1452. 2019
- Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.. 53:1278-1287. 2018
- Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation.. 53:1079-1082. 2018
- Biomarkers in chronic graft-versus-host disease: quo vadis?. 53:832-837. 2018
- Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.. 53:932-937. 2018
- High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.. 53:34-38. 2018
- Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2.. 52:1575-1576. 2017
- Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.. 52:1483-1484. 2017
- B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.. 52:1010-1015. 2017
- Cognitive problems following hematopoietic stem cell transplant: relationships with sleep, depression and fatigue.. 52:279-284. 2017
- Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.. 51:1191-1196. 2016
- Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN.. 51:1173-1179. 2016
- Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.. 51:938-944. 2016
- Personalized home-based interval exercise training may improve cardiorespiratory fitness in cancer patients preparing to undergo hematopoietic cell transplantation.. 51:967-972. 2016
- Regionalization of stem cell transplant procedures into teaching hospitals in United States: are we ready?. 51:1004-1006. 2016
- Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.. 51:732-734. 2016
- Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.. 51:607-609. 2016
- Prevalence, predictors and outcomes of cardiopulmonary resuscitation in hospitalized adult stem cell transplant recipients in the United States: not just opening the black box but exploring an opportunity to optimize!. 50:1578-1581. 2015
- Umbilical cord blood donation: public or private?. 50:1271-1278. 2015
- Important impact of gingival and periodontal conditions on outcomes in SCT recipients.. 50:604-606. 2015
- Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.. 50:367-374. 2015
- Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.. 49:1330-1336. 2014
- Outcomes of stem cell transplant patients with acute respiratory failure requiring mechanical ventilation in the United States.. 49:1278-1286. 2014
- Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.. 48:1444-1449. 2013
- Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study.. 48:1342-1349. 2013
- Long-term outcome of non-ablative booster BMT in patients with SCID.. 48:1050-1055. 2013
- Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.. 48:926-931. 2013
- Rescuing the neonatal brain from hypoxic injury with autologous cord blood.. 48:890-900. 2013
- Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.. 48:771-776. 2013
- Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.. 47:1283-1286. 2012
- Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.. 47:1350-1355. 2012
- Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.. 47:1051-1055. 2012
- Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.. 47:817-823. 2012
- Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.. 47:700-705. 2012
- Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients.. 47:352-359. 2012
- Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.. 46:847-851. 2011
- Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells.. 45:379-384. 2010
- Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.. 44:739-748. 2009
- Umbilical cord blood transplantation for non-malignant diseases.. 44:643-651. 2009
- Auto-SCT for AML in second remission: CALGB study 9620.. 44:353-359. 2009
- Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study.. 44:339-343. 2009
- Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis.. 44:387-389. 2009
- Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.. 44:89-96. 2009
- Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.. 43:327-333. 2009
- Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. 2022